Document is current
Any future updates will be listed below
-
Authors
Grinde, Bjørn https://orcid.org/0000-0003-1216-2851
Schirmer, Henrik
Eggen, Anne Elise
Aigner, Ludwig
Engdahl, Bo
-
Funding
Funding for this research was provided by:
Norwegian Institute of Public Health
- License Information
-
More Information
Article History
Received: 23 April 2020
Accepted: 17 September 2020
First Online: 9 October 2020
Conflicts of interest
: LA declares that he is consultant at IntelGenx corp., Canada, which has a clinical program for the development of Montelukast in AD. The other authors declare that they have no competing interests.
